Is Caplyta (lumateperone) indicated for bipolar I disorder or bipolar II disorder?

Caplyta is FDA-approved for BOTH bipolar I and bipolar II disorder

Caplyta (lumateperone) is indicated for depressive episodes associated with both bipolar I disorder and bipolar II disorder, making it equally appropriate for either diagnosis. 1

FDA-Approved Indications

According to the FDA drug label, Caplyta has two approved indications 1:

1. Schizophrenia in adults
2. Depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, both as:
   • Monotherapy (used alone)
   • Adjunctive therapy with lithium or valproate

Clinical Evidence Supporting Both Subtypes

The pivotal clinical trials specifically enrolled patients with both bipolar I and bipolar II disorder experiencing major depressive episodes:

Monotherapy Studies

• Study design: Patients with bipolar I or bipolar II disorder were randomized to lumateperone 42 mg versus placebo 2
• Results: Lumateperone demonstrated significant superiority over placebo in both bipolar I and bipolar II subgroups separately
• Effect size: MADRS improvement of -4.6 points versus placebo (effect size = -0.56) 2

Adjunctive Therapy Studies

• Study design: Patients with inadequate response to lithium or valproate received adjunctive lumateperone 3
• Results: Lumateperone 42 mg showed significant improvement in MADRS scores (-2.4 points vs placebo, p=0.02) in patients with both bipolar I and bipolar II disorder 3

Key Clinical Distinction

Caplyta is the only FDA-approved agent specifically indicated as adjunctive therapy for bipolar II depression 4. This is particularly noteworthy because:

• Traditional mood stabilizers and antipsychotics have historically focused on bipolar I disorder
• Bipolar II depression often requires different treatment considerations than bipolar I
• The approval for both subtypes reflects robust efficacy data across the bipolar spectrum

Practical Prescribing Considerations

For Bipolar I patients:

• Antimanic therapy should be established for at least 2-4 weeks before initiating Caplyta to prevent manic switches 5
• Can be used as monotherapy or adjunctive to lithium/valproate

For Bipolar II patients:

• The need for concurrent mood stabilizer coverage may be at clinician's discretion given lower risk of manic episodes 5
• Particularly valuable as the only approved adjunctive option for bipolar II depression 4

Safety Profile Across Both Subtypes

The medication demonstrated consistent tolerability in both bipolar I and II populations 2, 3:

• Minimal extrapyramidal symptoms (similar to placebo)
• Low risk of metabolic abnormalities
• Minimal weight gain or prolactin elevation
• Low incidence of treatment-emergent mania/hypomania in both groups 6

Bottom line: Caplyta does not favor one bipolar subtype over the other—it is equally indicated and effective for depressive episodes in both bipolar I and bipolar II disorder, with the unique distinction of being the only approved adjunctive treatment specifically for bipolar II depression.